195 related articles for article (PubMed ID: 22527961)
21. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY
Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405
[TBL] [Abstract][Full Text] [Related]
22. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
Komrokji RS; Seymour JF; Roberts AW; Wadleigh M; To LB; Scherber R; Turba E; Dorr A; Zhu J; Wang L; Granston T; Campbell MS; Mesa RA
Blood; 2015 Apr; 125(17):2649-55. PubMed ID: 25762180
[TBL] [Abstract][Full Text] [Related]
23. Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor.
Lou YJ
Acta Pharmacol Sin; 2012 Feb; 33(2):212-3. PubMed ID: 22231396
[No Abstract] [Full Text] [Related]
24. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
25. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
Tremblay D; Mascarenhas J
Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
[TBL] [Abstract][Full Text] [Related]
26. Acid Mediated Ring Closing Metathesis: A Powerful Synthetic Tool Enabling the Synthesis of Clinical Stage Kinase Inhibitors.
William AD; Lee AC
Chimia (Aarau); 2015; 69(3):142-5. PubMed ID: 26507218
[TBL] [Abstract][Full Text] [Related]
27. Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate.
Zhu J; Yang T; Tang M; Yang Z; Pei H; Ye H; Tang Y; Cheng Z; Lin P; Chen L
Biomed Pharmacother; 2021 May; 137():111373. PubMed ID: 33761599
[TBL] [Abstract][Full Text] [Related]
28. Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.
Ma X; Diao Y; Ge H; Xu F; Zhu L; Zhao Z; Li H
Bioorg Med Chem Lett; 2020 Apr; 30(8):127048. PubMed ID: 32122740
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Younes A; Romaguera J; Fanale M; McLaughlin P; Hagemeister F; Copeland A; Neelapu S; Kwak L; Shah J; de Castro Faria S; Hart S; Wood J; Jayaraman R; Ethirajulu K; Zhu J
J Clin Oncol; 2012 Nov; 30(33):4161-7. PubMed ID: 22965964
[TBL] [Abstract][Full Text] [Related]
31. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP
J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660
[TBL] [Abstract][Full Text] [Related]
32. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.
Hart S; Goh KC; Novotny-Diermayr V; Tan YC; Madan B; Amalini C; Ong LC; Kheng B; Cheong A; Zhou J; Chng WJ; Wood JM
Blood Cancer J; 2011 Nov; 1(11):e44. PubMed ID: 22829080
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
Liang X; Huang Y; Zang J; Gao Q; Wang B; Xu W; Zhang Y
Bioorg Med Chem; 2016 Jun; 24(12):2660-72. PubMed ID: 27137359
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
Wang T; Liu X; Hao M; Qiao J; Ju C; Xue L; Zhang C
Bioorg Med Chem Lett; 2016 Jun; 26(12):2936-2941. PubMed ID: 27130359
[TBL] [Abstract][Full Text] [Related]
36. Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors.
Wang Y; Huang W; Xin M; Chen P; Gui L; Zhao X; Tang F; Wang J; Liu F
Bioorg Med Chem; 2017 Jan; 25(1):75-83. PubMed ID: 27771180
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
[TBL] [Abstract][Full Text] [Related]
38. Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.
Yuan X; Chen Y; Zhang W; He J; Lei L; Tang M; Liu J; Li M; Dou C; Yang T; Yang L; Yang S; Wei Y; Peng A; Niu T; Xiang M; Ye H; Chen L
J Med Chem; 2019 Apr; 62(8):4158-4173. PubMed ID: 30939008
[TBL] [Abstract][Full Text] [Related]
39. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
[TBL] [Abstract][Full Text] [Related]
40. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
De SK
Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]